OUR PLATFORM

Pioneering Spirit
& Ambition

QurAlis is breaking through the barriers of science in our quest to bring much-needed precision therapies to patients.

FlexASO®: Proprietary Anti-Sense Oligonucleotide Splice Modulator Platform

Team

Pipeline

Culture

Patients

February 23, 2026

QurAlis Demonstrates Effects on Disease Progression and Target Engagement in ANQUR Clinical Trial of QRL-201, a First-in-Class Precision Medicine in Development for Sporadic ALS

December 29, 2025

QurAlis Confirms Signal of Target Engagement in ALS Patients in Phase 1 Clinical Trial of QRL-101, a Potentially Best-in-Class Selective Kv7.2/7.3 Ion Channel Opener

December 18, 2025

QurAlis Invited to Present at 44th Annual J.P. Morgan Healthcare Conference

December 2, 2025

QurAlis to Present Data From its Phase 1 Clinical Trial of QRL-101, a Potential Best-in-Class Selective Kv7.2/7.3 Ion Channel Opener, at American Epilepsy Society 2025 Annual Meeting